Literature DB >> 1245091

Disposition kinetics of quinidine.

C T Ueda, D S Hirschfeld, M M Scheinman, M Rowland, B J Williamson, B S Dzindzio.   

Abstract

The disposition kinetics of quinidine in 12 hospitalized patients in whom oral quinidine therapy was to be initiated is described. Quinidine in doses of 2.6 to 5.2 mg/kg base were infused intravenously over 22 min. Plasma samples were collected during the postinfusion for 24 hr and analyzed by a specific and sensitive assay procedure. In the 12 hr after administration, postinfusion plasma quinidine concentration decay was described by a biexponential equation. Attempts to include the 24-hr data point in the fitting procedures resulted in poorer agreements between the theoretical and experimental curves. A 2-compartment open model is proposed to describe the disposition of quinidine. The volume of the central pool (Vc) and steady-state volume of distribution (Vdss) were 0.91 +/- 0.11 L/kg and 3.03 +/- 0.25 L/kg, respectively, and indicate that quinidine distribution is predominantly extravascular. Quinidine distribution was quite rapid (t1/2alpha = 7.19 +/- 0.70 min), while the apparent elimination half-life (t1/2beta) was considerably longer, 6.333 +/- 0.47 hr. Total body plasma clearance ranged from 1.49 to 7.15 ml/min/kg (mean 4.70) and is primarily associated with nonrenal mechanisms of drug elimination. Urine specimens collected for 48 hr indicated that 17% of the dose is excreted intact and that urinary excretion was essentially complete within 24 hr. Renal clearance (Clr) was 0.80 +/- 0.18 ml/min/kg. The study demonstrated that there is substantial interpatient variability with respect to quinidine disposition.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1245091     DOI: 10.1002/cpt197619130

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.

Authors:  G M Frigo; E Perucca; M Teggia-Droghi; G Gatti; A Mussini; J Salerno
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

3.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

4.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

6.  Comparative bioavailability study of three sustained release quinidine formulations.

Authors:  W A Mahon; J S Leeder; M M Brill-Edwards; J Correia; S M MacLeod
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

7.  Pharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administration.

Authors:  C T Ueda; B S Dzindzio
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 8.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

9.  Isolation, characterisation and synthesis of a new quinidine metabolite.

Authors:  T W Guentert; J J Daly; S Riegelman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

10.  Bioavailability of quinidine in congestive heart failure.

Authors:  C T Ueda; B S Dzindzio
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.